Clinical Trials
Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data
Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients...
Business & Industry
J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant
Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move...
News
Precision Cellular Analysis Powering the Next Generation
Biopharmaceutical innovation increasingly depends on understanding biology at the cellular level. As therapies become more targeted and personalized, researchers must analyze how individual cells...
Business & Industry
FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC
Johnson & Johnson (J&J) has obtained approval from the US Food and Drug Administration (FDA) for a revised dosing schedule of Rybrevant Faspro (amivantamab...
BioPharma
European Commission Approves Exdensur – depemokimab
On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications -
As an add-on maintenance treatment when it...
Business & Industry
Sanofi to Expand Its Global Capability Centre in Hyderabad
In a move that is sure to create a stir within the Asia pharma circle, Sanofi Healthcare India - SHIPL is going ahead and...
Business & Industry
Gilead Secures GH31 Global Rights in $80M Oncology Deal
Gilead Sciences has added another synthetic lethal asset to its oncology portfolio, agreeing to pay $80 million upfront to obtain global rights to a...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read